Projects 

We create decision-relevant information in the form of scientific publications with a global audience. We have research expertise and prepare our analyses in accordance with good scientific practice and established guidelines (for example, the CHEERS guidelines for publishing cost-effectiveness analyses). In projects with an exclusively Norwegian focus, such as economic analyses of the organisation of health services within Norway, we strive to adhere closely to Norwegian guidelines for method assessments in order to generate the most decision-relevant information as possible.

Examples of Finished Projects

Project

Year

Health Economist

Publication

Health economic evaluation of mobile x-ray services for nursing home patients in South-Eastern Norway Regional Health Authority (HSØ)

2018

L. Kleven, H.O. Melberg

https://doi.org/10.1111/jep.13058

 

Health economic evaluation of surgery compared with non-surgical treatment in wrist fractures for elderly patients

2020

Z. Zolic-Karlsson

https://doi.org/10.1302/2633-1462.212.BJO-2021-0108.R1

Health economic evaluation of an online intervention programme for young people with a visible difference

2022

L. Asphaug

https://doi.org/10.1111/sjop.12885

Examples of Ongoing Projects

Project

Phase

Periode (year from-till)

Health Economist

 

Analysis

2015-2023

M. Vervaart

Medical prevention of complications for elderly stroke patients

In this EU-funded project, the cost-effectiveness of the drugs ceftriaxone, paracetamol and metocolpramide are compared for the prevention of complications in acute strokes in elderly patients. The project is led by Utrecht University, the Netherlands. We are the work package manager and implementation unit for the health economic evaluation. The analysis combines study data with external data in a model to project the effect of the various treatment options on quality-adjusted life years (QALYs) and treatment costs.

 

Analysis

2022-2023

L. Asphaug

Effect and priority considerations of the treatment at Modum Bad

Modum Bad is a private hospital with an agreement with Helse Sør-Øst to offer specialist healthcare services within mental health care to patients who have not achieved a treatment effect at a local specialist healthcare service. The hospital has collected quality of life data (SF-36) for its patients for a number of years and this data is used in an analysis where we will determine Modum Bad's patients' health loss before treatment in relation to the general population. The project will also determine the effect on quality-adjusted life years (QALYs) achieved by the treatment at the hospital. In addition, we will examine whether the hospital's operating costs per patient will be within the authorities' upper payment limits for health benefits for patients who have a loss of health similar to Modum Bad's patients.

 

Reporting

2022-2023

L. Asphaug

Economic evaluation of changing the first responsible treatment for hand osteoarthritis patients from rheumatologists to occupational therapists

The project originates from a randomized controlled trial (non-inferiority) carried out at Diakonhjemmet Hospital and Martina Hansen's hospital under the leadership of Ingvild Kjeken. The study randomized patients with hand osteoarthritis to either be initially treated by a rheumatologist or an occupational therapist. Information was collected on quality of life measured with the instrument EQ-5D. These measurements were used to quality-adjust the patients' time in the trial to determine whether differences in quality-adjusted life years can be expected by changing the treating occupational group. In addition, information was collected on the health service's resource use per patient. This was used to calculate a cost per patient. The hypothesis is that one will not observe a statistically meaningful difference in health effect, as well as a lower average treatment cost in patients treated by an occupational therapist.

The technical documentation for the economic evaluation has been completed and a manuscript is being prepared for scientific publication.

 

Reporting

2022-2023

L. Asphaug

Comparison of direct costs of caesarean section using either oxytocin or carbetocin

The drug oxytocin has long been used in connection with caesarean sections. The alternative, carbetocin, has a significantly higher cost per dose, but fewer associated complications, which can be thought to result in a shorter total time in the operating room than oxytocin. The project will compare total direct costs in the operating theatre. The underlying clinical study was carried out as a randomized controlled trial at Rikshospitalet under the leadership of Leiv Arne Rosseland.

The hypothesis is that one will not observe a statistically meaningful difference in total treatment costs, it is assumed that carbetocin costs approximately ten times more than oxytocin. 

 

 
Page visits: 422